IJMPD | Formulation and Evaluation of Floating in Situ Gel of Lafutidine

Indexing and Abstracting

Formulation and Evaluation of Floating in Situ Gel of Lafutidine

Vijay Kumar Damodhar , Rukhsana Mahiboob Pinjari

International Journal of Medical, Pharmacy and Drug Research(IJMPD), Vol-7,Issue-5, October - December 2023, Pages 8-14 ,

Download | Downloads : 2 | Total View : 310

Article Info: Received: 08 Aug 2023; Received in revised form: 13 Sep 2023; Accepted: 21 Sep 2023; Available online: 30 Sep 2023

Abstract:

Gastroesophageal reflux disease (GERD) and peptic ulcers are prevalent gastrointestinal disorders that significantly impact the quality of life of affected individuals. Lafutidine, a histamine H2-receptor antagonist, has demonstrated effectiveness in managing these conditions. However, its short gastric residence time limits its therapeutic efficacy. To address this limitation, we aimed to formulate and evaluate a floating in situ gel of Lafutidine for prolonged gastric retention and enhanced therapeutic outcomes. In vivo studies were conducted on albino Wistar rats to assess the pharmacokinetic parameters and gastric residence time. The pharmacokinetic evaluation demonstrated that the floating in situ gel exhibited improved Lafutidine bioavailability compared to the conventional dosage form. Gastric residence time was significantly extended, enhancing Lafutidine's therapeutic efficacy. Overall, the formulation and evaluation of the floating in situ gel of Lafutidine demonstrated its potential as an effective drug delivery system for the management of GERD and peptic ulcers. The extended gastric retention and enhanced bioavailability of Lafutidine make this formulation a promising option for improving patient compliance and therapeutic outcomes in the treatment of these gastrointestinal disorders. Further clinical studies are warranted to establish its clinical efficacy and safety profile.

Keywords:

In situ gel, Gastroesophageal reflux disease, omeprazole magnesium, In vitro floating duration, In vitro gelling capacity bioavailability, Gastric resident time.

References:

[1] Naseem F, Shah SU, Rashid SA, Farid A, Almehmadi M, Alghamdi S. (2022), Metronidazole Based Floating Bioadhesive Drug Delivery System for Potential Eradication of H. pylori: Preparation and In Vitro Characterization. Polymers (Basel). Jan 27;14(3):519. doi: 10.3390/polym14030519. PMID: 35160508; PMCID: PMC8838680.
[2] Asmaa H. Esmaeil, Afaf A. Ramadan, Asmaa M. Elbakry (2020), Development and Characterization of In Situ Gel Containing Leflunomide as a Gastro-retentive Drug Delivery, Int. J. Pharm. Sci. Rev. Res., 64(2).
[3] Srebro, Justyna, Witold Brniak, and Aleksander Mendyk. 2022. "Formulation of Dosage Forms with Proton Pump Inhibitors: State of the Art, Challenges and Future Perspectives" Pharmaceutics 14, no. 10: 2043. https://doi.org/10.3390/pharmaceutics14102043
[4] Pandya K, Aggarwal P, Dashora A, Sahu D, Garg R, Pareta L, Menaria M, Joshi B. (2013), FORMULATION AND EVALUATION OF ORAL FLOATABLE IN-SITU GEL OF RANITEDINE HYDROCHLORIDE. JDDT [Internet]. 13May2013 [cited 7Sep.2023];3(3):90-7. Available from: https://jddtonline.info/index.php/jddt/article/view/516
[5] Sharma A, Sharma J, Kaur R, Saini V. (2014), Development and characterization of in situ oral gel of spiramycin. Biomed Res Int. 2014;2014:876182. doi: 10.1155/2014/876182. Epub 2014 Jun 24. PMID: 25050376; PMCID: PMC4094871.
[6] Thomas LM. Formulation and evaluation of floating oral in-situ gel of metronidazole. Int J Pharm Pharm Sci 2014;6:205-9.
[7] Suvakanta D. Kinetic modeling on drug release from controlled drug delivery systems. Actapoloniaepharm Drug Res 2012;67:217-23.
[8] Frances S, John T. A review on in situ floating gel of telmesartan. Int J Pharm 2018;3:301-11.
[9] Kumar R, Singh H, Singh P. Development of UV Spectrophotometric method for estimation of pantoprazole in pharmaceutical dosage forms. J Chem Pharm Res 2017;3:113-7.
[10] Devault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2015;100:190-200.
[11] Li S, Mirchandani HL, Chien TW. Effect of formulation variables on the floating properties of gastric floating drug delivery system. Drug Dev Ind Pharm 2012;28:783-93.
[12] Darekar AB, Patil VA, Gondkar SB. Development and characterization of novel in-situ floating gel of levocetirizine dihydrochloride for oral drug delivery system. Der Pharm Lett 2016;8:188-96.
[13] Rathod HJ, Mehta DP, Yadav JS. A review on Gastroretentive Drug Delivery Systems. Pharma Tutor. 2016; 4(7): 29-40.
[14] assal M, Nautiya U, Kundlas J, Singh D. A review: Gastroretentive drug delivery system (GRDDS). Indian Journal of Pharmaceutical and Biological Research (IJPBR). 2015; 3(1): 82-92.
[15] Hala SY, Yehia IK. In situ Gelling Formulation of Naproxen for Oral Sustained Delivery System. Iraqi Journal of Pharmaceutical Sciences. 2019; 18(1): 13-20.